Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MTM and DAKO link up on cancer diagnostics:

This article was originally published in Clinica

Executive Summary

German company MTM Laboratories and DAKO, of Copenhagen, Denmark, have formed a cancer screening licensing and product development deal. DAKO gets exclusive, worldwide rights to MTM's CINtec molecular technology, which is aimed at early identification of cervical cancer. The two companies plan to develop the technology for the diagnosis of other types of tumours. MTM will get undisclosed upfront, milestone, R&D and royalty payments. DAKO has considerable experience in moving cell-based diagnostics through the regulatory process to market and will significantly shorten MTM's time to market, Heidelberg-based MTM says.

Topics

UsernamePublicRestriction

Register

MT074051

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel